Payment overview · 2025
General Payments
$148.82
8 reported records · 4 companies
Healthcare provider profile · identity verified
Jay L Wedel, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · HESSTON, KS · NPI 1427003177
Verified facts
What the public records show
CMS Open Payments records show Jay L Wedel, PAC received $148.82 in general payments during 2025 across 8 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 35.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $52.54 | 35.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.24 | 25.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.53 | 20.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.51 | 19.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $148.82 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $52.54 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.24 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.24 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.53 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 245 | 67 |
| Losartan Potassium | Losartan Potassium | 161 | 50 |
| Memantine Hcl | Memantine Hcl | 131 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 127 | 39 |
| Omeprazole | Omeprazole | 125 | 38 |
| Donepezil Hcl | Donepezil Hcl | 121 | 39 |
| Famotidine | Famotidine | 119 | 43 |
| Lisinopril | Lisinopril | 115 | 40 |
| Pregabalin | Pregabalin | 110 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 30 |
| Celecoxib | Celecoxib | 102 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 102 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 99 | 32 |
| Metformin Hcl | Metformin Hcl | 92 | 31 |
| Trazodone Hcl | Trazodone Hcl | 90 | 32 |
| Mounjaro | Tirzepatide | 86 | 15 |
| Prednisone | Prednisone | 83 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 22 |
| Tramadol Hcl | Tramadol Hcl | 82 | 27 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 78 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 14 |
| Sertraline Hcl | Sertraline Hcl | 77 | 25 |
| Azithromycin | Azithromycin | 73 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | 24 |
| Gabapentin | Gabapentin | 69 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 67 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 66 | 16 |
| Clonazepam | Clonazepam | 62 | suppressed |
| Meloxicam | Meloxicam | 62 | 24 |
| Methylprednisolone | Methylprednisolone | 61 | 39 |
| Montelukast Sodium | Montelukast Sodium | 61 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 13 |
| Alprazolam | Alprazolam | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 47 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 47 | suppressed |
| Ibuprofen | Ibuprofen | 47 | 15 |
| Temazepam | Temazepam | 44 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | 14 |
| Simvastatin | Simvastatin | 42 | 11 |
| Carvedilol | Carvedilol | 41 | suppressed |
| Allopurinol | Allopurinol | 40 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 21 |
| Ondansetron Odt | Ondansetron | 39 | 21 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 24 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Furosemide | Furosemide | 37 | 14 |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 35 | 20 |
| Potassium Chloride | Potassium Chloride | 33 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Eliquis | Apixaban | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 30 | 19 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | 12 |
| Estradiol | Estradiol | 28 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Baclofen | Baclofen | 24 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Testosterone | Testosterone | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Glipizide Er | Glipizide | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $148.82 · 8 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, CAPLYTA, FARXIGA, MOUNJARO, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error